bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 million
BIAF•Quarterly results and operating costs
bioAffinity Technologies posted Q2 revenue of USD 1.5 million, up 19% year over year; net loss narrowed to USD 3.4 million.
Operating expenses increased to USD 4.8 million from USD 3.8 million, reflecting higher clinical development and SG&A spending.
CyPath Lung growth and management focus
CyPath Lung test volume rose 216% from Q2 2025; physician offices and clinics ordering the test increased 122%.
First-half CyPath Lung testing revenue climbed 159% to about USD 835,000; 1,097 test reports were delivered.
Management flagged priorities for the second half: expanding physician adoption, lifting existing-customer utilization, entering new systems including oncology.
